Roche to Present its Oncology Portfolio at the ESMO Virtual Congress 2020

 Roche to Present its Oncology Portfolio at the ESMO Virtual Congress 2020

Roche to Present its Oncology Portfolio at the ESMO Virtual Congress 2020

Shots:

  • Roche highlights data from three P-III studies across the Tecentriq (atezolizumab) TNBC programme, CNS efficacy data from integrated analyses of the pivotal Rozlytrek (entrectinib) clinical development program, and the data from the registrational P-I/II ARROW trial assessing Gavreto (pralsetinib) for RET-mutant MTC patients
  • Data from the P-III IPATential150 study in mCRPC patients and whose tumors had PTEN loss will also be presented
  • Roche will be hosting a live roundtable discussion focusing on COVID-19 and the impact it may have on the outcomes for cancer patients. The discussion will focus on potential solutions and the lessons have been learned from the pandemic so far

Click here ­to­ read full press release/ article | Ref: Roche | Image: CNBC

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post